Alnylam Pharmaceuticals
ALNY
#569
Rank
NZ$72.10 B
Marketcap
NZ$543.69
Share price
-1.75%
Change (1 day)
29.49%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): NZ$0.31

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is NZ$0.16. In 2023 the company made an earnings per share (EPS) of NZ-$6.10 an increase over its 2022 EPS that were of NZ-$16.04.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)NZ$0.31
2023NZ-$6.10-62%
2022NZ-$16.0429.03%
2021NZ-$12.44-3.36%
2020NZ-$12.87-8.48%
2019NZ-$14.067.67%
2018NZ-$13.0639.74%
2017NZ-$9.3412.94%
2016NZ-$8.2738.84%
2015NZ-$5.96-32.88%
2014NZ-$8.88259.44%
2013NZ-$2.47-31.25%
2012NZ-$3.59

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
NZ$12.71 8,077.78%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
NZ$3.57 2,194.62%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
NZ$74.47 47,811.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
NZ-$4.73-3,144.44%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
NZ-$1.26-911.11%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
NZ-$0.41-366.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
NZ$2.14 1,277.78%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
NZ-$2.16-1,488.89%๐Ÿ‡บ๐Ÿ‡ธ USA